drugset / Trial / NCT06025344
A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
RandomizedCrossoverOpen-labelTreatment
Summary
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100 mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under fasting conditions.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2024-09-30
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PanCytoVir™ | Unknown | 1000 mg | Oral |
| Subject | Probenecid | Small molecule | 1000 mg | Oral |
Indications
No indication recorded.